-citabine
Nucleoside drugs related to cytarabine or azacitidine, used for cancer or viruses.
- Drugs ending in -citabine: 22
- Approved somewhere: 5
- With a US drug page: 6
- Stem
- -citabine
- Class
- Nucleoside drugs related to cytarabine or azacitidine, used for cancer or viruses
- Most common targets
- POL (5), DNA (4), Ribonucleoside-diphosphate reductase RR1 (2), DNA polymerase (alpha/delta/epsilon) (2), P (2), NS5B (2), TYMS (1), RNA (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -citabine, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Capecitabine | Approved | TYMS, DNA, RNA | Thymidylate synthase inhibitor |
| Decitabine | Approved | DNMT3A, DNMT1, DNA | DNA (cytosine-5)-methyltransferase 3A inhibitor |
| Emtricitabine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Gemcitabine | Approved | Ribonucleoside-diphosphate reductase RR1, DNA polymerase (alpha/delta/epsilon) | Ribonucleoside-diphosphate reductase RR1 inhibitor |
| Zalcitabine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Emtricitabine, (+/-)- | Phase 2 | — | — |
| Apricitabine | Phase 3 | POL, REVERSE, TRANSCRIPTASE | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Fosgemcitabine palabenamide | Phase 3 | — | — |
| Guadecitabine | Phase 3 | — | — |
| Sapacitabine | Phase 3 | DNA | DNA inhibitor |
| Dexelvucitabine | Phase 2 | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Elvucitabine | Phase 2 | POL, P | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Ibacitabine | Phase 2 | — | — |
| Lumicitabine | Phase 2 | L | RNA-directed RNA polymerase L inhibitor |
| Mericitabine | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Tezacitabine anhydrous | Phase 2 | Ribonucleoside-diphosphate reductase RR1 | Ribonucleoside-diphosphate reductase RR1 inhibitor |
| Troxacitabine | Phase 2 | DNA polymerase (alpha/delta/epsilon) | DNA polymerase (alpha/delta/epsilon) inhibitor |
| Valopicitabine | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Valtorcitabine | Phase 2 | DNA, P | DNA inhibitor |
| Fostroxacitabine bralpamide | Phase 1 | — | — |
| Gemcitabine elaidate | Phase 1 | — | — |
| Roducitabine | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO